Harmony Biosciences Holdings, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year 2023 and for the Year 2024
The net product revenue for the full year ended December 31, 2023, was approximately $582 million, compared to $437.9 million for the same period in 2022, representing approx. 33% growth.
The company also provided 2024 net product revenue guidance of $700 to $720 million.